WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that five abstracts, describing FOLOTYN® (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year’s 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
